LinkedIn Icon
May 4-6, 2020 | Boston, MA

Seminar Day

To view these sessions in full download the brochure

Seminar Day: Monday April 22

Non-Invasive Biomarkers Deep Dive

Commercial Leaders Day

Non-Invasive Biomarkers: What Do We Have? Drug to Clinic: How Do We Get There?
09.30 Review & Analysis of the Current Non-Invasive 09.30 Considerations of a Payer for Non-Alcoholic Steatohepatitis
09.45 LITMUS – Valorizing the European NAFLD Registry
10.00 Future NASH Commercial Landscape
10.15 NIMBLE Project: Finding Non-Invasive Biomarkers for NASH (FNIH Biomarkers Consortium)
10.30 Designing Clinical Trials in Pediatric NASH: From
Patient Selection to Endpoints & Beyond
10.45 Extended Q&A for NIMBLE & LITMUS 11.00 Morning Break & Networking
11.00 Morning Break & Networking Drug to Clinic: How Do We Get There? (Continued)
Technology Showcase:Quantifying Fibrosis Through Non-Invasive
11.45 Potential Impact & Value of NASH Therapies
11.45 Multiparametric Imaging: Translating Preclinical
Observations into Human Trial
12.15 Panel Discussion: What Can We Understand About the Pricing & Reimbursement Landscape?

12.45 Lunch & Networking

Innovations to Enhance the Utility of Biomarkers for
Fatty & Fibrotic Liver Disease

Insights into Investment & Market Development
01.45 Exploring the Translatability of NASH Biomarkers 01.45 Panel Discussion: How do we Build Investor Confidence in NASH Pipelines?

02.15 Machine Learning for NASH Biomarkers
02.45 Developing an In Vitro Diagnostic Test (IVD) in
Parallel to Advancing a Drug Candidate
03.15 Chair’s Summary
02.30 Chair’s Summary
Keynotes & Networking Evening